Nivolumab and Combination Chemotherapy in Treating Participants With Diffuse Large B-Cell Lymphoma
Status:
Recruiting
Trial end date:
2023-06-11
Target enrollment:
Participant gender:
Summary
This phase I/II trial studies the side effects and best dose of nivolumab and how well it
works when giving together with combination chemotherapy in treating participants with
diffuse large B-cell lymphoma. Monoclonal antibodies, such as nivolumab, interfere with the
ability of cancer cells to grow and spread. Drugs used in chemotherapy, work in different
ways to stop the growth of cancer cells, either by killing the cells, by stopping them from
dividing, or by stopping them from spreading. Giving nivolumab and combination chemotherapy
may work better in treating participants with diffuse large B-cell lymphoma.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Northwestern University
Collaborators:
Bristol-Myers Squibb Bristol-Myers Squibb (BMS) National Cancer Institute (NCI)